



Cxbladder News Bulletin: July 2025

Dear Customers and Friends of Cxbladder,

Welcome to the July 2025 edition of the Cxbladder Bulletin. In this issue:

- **Watch Now:** View Webinars From UroToday's AUA 2025 Series
 - **Advancing Microhematuria Evaluation: The Impact of Urinary Biomarkers and Updated Guidelines** - Dr. Jay D. Raman & Dr. Yair Lotan
 - **Cxbladder Platform Reduces Unnecessary Cystoscopies** - Dr. John Sfakianos
 - **Improving Diagnosis and Treatment of Microhematuria** - Kaiser Permanente's Dr. Ronald Loo and Dr. Christopher Filson
- **Watch Now:** Cxbladder for Hematuria Evaluation and Bladder Cancer Surveillance: Dr. Tamer Aboushwareb - View the APAC webinar below
- UAA 2025 invite
- Marking Bladder Cancer Awareness Month in May

UroToday Marks AUA/SUFU Microhematuria Guideline Update & AUA 2025 with Webinar Series

In late February, the AUA published a significant amendment to its AUA/SUFU

Microhematuria Guideline¹, incorporating language for the use of urine-based biomarkers in intermediate-risk patients. The update specifically mentioned Cxbladder Triage with supporting 'Grade A' evidence.

Guideline Statement 13: *"In appropriately counseled intermediate-risk patients who want to avoid cystoscopy and accept the risk of forgoing direct visual inspection of the bladder urothelium, clinicians may offer urine cytology or validated urine-based tumor markers (Table 5) to facilitate the decision regarding utility of cystoscopy. Renal and bladder ultrasound should still be performed in these cases."*¹

In addition, the guideline states: *“The highest level of evidence was an evaluation of Cxbladder Triage based on an RCT comparing a marker-based approach versus standard of care routine cystoscopy to evaluate MH. In this study, the marker had a NPV of 99%”*¹

The amended Guideline was a focal point throughout AUA 2025 in late April, and in conjunction with the event, UroToday collaborated with leading US urologists to produce a series of webinars focused on the Guideline update and the latest real-world evidence supporting the use of UBTMs in hematuria evaluation.

Advancing Microhematuria Evaluation: The Impact of Urinary Biomarkers and Updated Guidelines - Dr. Jay D. Raman & Dr. Yair Lotan

Dr. Jay Raman and Dr. Yair Lotan sit down with Dr. Zachary Klaassen to discuss the latest developments in microhematuria evaluation. Topics include the unmet need in risk stratifying patients, the evolution of the AUA/SUFU Microhematuria Guideline from 2020 to 2025, and the role of urinary biomarkers in optimizing patient care, including Cxbladder Triage, a test now incorporated into the Guideline¹, with supporting “Grade A” evidence.

[View](#) the webinar on UroToday.



Cxbladder Platform Reduces Unnecessary Cystoscopies – Dr. John Sfakianos

Dr. Zachary Klaassen interviews Dr. John Sfakianos about implementing the Cxbladder platform for microhematuria risk stratification and bladder cancer surveillance. Dr. Sfakianos discusses how high-quality biomarkers address the longstanding need to avoid over-diagnosing patients with microhematuria, where historically everyone received cystoscopy despite most having no significant findings. He describes using two Cxbladder tests routinely: Triage for microhematuria patients, and Monitor for bladder cancer surveillance.

[View](#) the webinar on UroToday.




Improving Diagnosis and Treatment of Microhematuria – Dr. Ronald Loo and Dr. Christopher Filson

Kaiser Permanente's Dr. Ronald Loo and Dr. Christopher Filson join Dr. Zachary Klaassen to discuss the real-world implementation of Cxbladder Triage within the Kaiser Health System for risk stratification, including the results of a retrospective real-world study of over 3,300 patients².

[View](#) the webinar on UroToday.





Cxbladder for Hematuria Evaluation and Bladder Cancer Surveillance: Dr. Tamer Aboushwareb

In late June, Pacific Edge Chief Medical Officer, Dr. Aboushwareb led an introductory webinar to a urological team in Malaysia.

Cxbladder is a suite of non-invasive genomic urine test optimized for the risk stratification of urothelial cancer in patients presenting with hematuria and those being monitored for recurrent disease. In his talk, Dr. Aboushwareb discussed the challenges clinical teams face and spoke to the utility of the Cxbladder suite, supported with recent data.

- Enhance risk stratification and de-intensify the evaluation of hematuria.
- Resolve atypical cytology and equivocal cystoscopy
- Reduce the burden of NMIBC surveillance cystoscopy
- Improve patient comfort, compliance and management

Watch Now: [View](#) the video.

Cx bladder™

2025 UAA
Taipei, Taiwan

Cxbladder tests are now included in the AUA/SUFU Microhematuria Guideline*.

Genomic testing optimized for the risk stratification of urothelial cancer

Come visit us at UAA2025 Booth #37 to learn more!

*Barocas DA, et al. Updates to Microhematuria: AUA/SUFU Guideline (2025). J Urol. 0(0). doi: 10.1097/JU.0000000000004490.

Marking Bladder Cancer Awareness Month in May

May is Bladder Cancer Awareness Month, a time for those affected by bladder cancer to stand together and raise awareness of the disease while working to better support its early detection, treatment and care.

This year our activities during the month again focused on raising awareness of the disease, while speaking directly to surveillance patients, emphasizing the importance of regular monitoring and compliance with scheduled checks. In support of this we presented Cxbladder Monitor as a non-invasive bladder cancer surveillance alternative that can reduce the frequency of cystoscopy required in those being monitored for recurrent non-muscle invasive bladder cancer. Recent [US survey data](#) suggests that patients have a strong interest in non-invasive testing, while a majority aren't aware of test options.



The Pacific Edge Team in Dunedin, New Zealand carry the orange theme in support of Bladder Cancer Awareness.

Contact Us

Email us: info@cxbladder.com

Visit us online at www.cxbladder.com

¹ Barocas DA, Lotan Y, Matulewicz RS, Raman JD, Westerman ME, Kirkbv E, Pak L, Souter L. Updates to Microhematuria: AUA/SUFU Guideline (2025). J Urol. doi: 10.1097/JU.0000000000004490.

² Loo R.K.. et al (2025) Clinical Utility of a Urine Biomarker (Cxbladder Triage) Compared to a Standard of Care for Microscopic Hematuria Evaluations in a Large Independent Delivery Network. Abstract submitted to the AUA 2025 meeting.

